Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma
- DOI
- 10.1038/mto.2015.19
- Published
- 2015
- Container
- Molecular Therapy - Oncolytics
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/mto.2015.19,
title = {Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma},
author = {Benjamin Ruf and Susanne Berchtold and Sascha Venturelli and Markus Burkard and Irina Smirnow and Tanja Prenzel and Stefan W Henning and Ulrich M Lauer},
year = {2015},
journal = {Molecular Therapy - Oncolytics},
doi = {10.1038/mto.2015.19},
url = {https://doi.org/10.1038/mto.2015.19}
}RIS
TY - JOUR TI - Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma AU - Benjamin Ruf AU - Susanne Berchtold AU - Sascha Venturelli AU - Markus Burkard AU - Irina Smirnow AU - Tanja Prenzel AU - Stefan W Henning AU - Ulrich M Lauer PY - 2015 JO - Molecular Therapy - Oncolytics DO - 10.1038/mto.2015.19 UR - https://doi.org/10.1038/mto.2015.19 ER -
APA
Ruf, B., Berchtold, S., Venturelli, S., Burkard, M., Smirnow, I., Prenzel, T., Henning, S. W., & Lauer, U. M. (2015). Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma. Molecular Therapy - Oncolytics. https://doi.org/10.1038/mto.2015.19
Source records
- crossref · retrieved 2026-09-25T12:16:16.961Z